A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

The protocol was amended to reflect the change from a phase 2/3 to a study with an expanded
access program (EAP) in the US that would include patients with ALCL and HL. A later
amendment allowed patients with CD30-positive cutaneous T-cell lymphoma to enroll. Enrollment
may continue and patients may receive brentuximab vedotin treatment on study until the drug
is commercially approved and available to patients in a geographic region.

Inclusion Criteria:

- Participated in either the SGN35-005 or C25001 clinical study and experienced
progression. Patients who received brentuximab vedotin in C25001 must have had an
objective response at the time of discontinuation.

- Completed any previous treatment with radiation, chemotherapy, biologics and/or
investigational agents at least 4 weeks prior to the first dose of brentuximab vedotin

Exclusion Criteria:

- History of another primary malignancy that has not been in remission for at least 3
years

- Known cerebral/meningeal disease

- Peripheral neuropathy of grade 2 or greater

- Females who are pregnant or breastfeeding